| 摘要 |
Methods are provided for treatment of lung cancers, particularly small cell lung cancer with targeted therapy. The therapy is targeted at one or more cell-surface antigens, including CD24, CD166, CD56, CD326, CD298, CD29, CD63, CD9, CD164, CD99, CD46, CD59, CD57, CD165, and EpCAM, which optionally includes an agent that selectively blocks CD47 binding to SIRPa. |
